デフォルト表紙
市場調査レポート
商品コード
1318844

希少医薬品市場:疾患タイプ、製品タイプ、流通チャネル別-2023-2030年の世界予測

Orphan Drugs Market by Disease Type, Product Type, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
希少医薬品市場:疾患タイプ、製品タイプ、流通チャネル別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

希少医薬品の世界市場は、2023年にCAGR 13.32%で1,918億6,000万米ドルと予測され、2030年には驚異的な4,624億5,000万米ドルに達すると予測され、大きく成長すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の希少医薬品市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展:有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化:新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向:COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション:将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします:

1.希少医薬品の世界市場規模および予測は?

2.予測期間中、世界の希少医薬品市場を形成するCOVID-19の阻害要因と影響は?

3.希少医薬品の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は?

4.希少医薬品の世界市場における競争戦略は?

5.希少医薬品の世界市場における技術動向と規制の枠組みは?

6.希少医薬品の世界市場における主要ベンダーの市場シェアは?

7.希少医薬品の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 希少疾患の罹患率の急増とヘルスケア費の増加
      • 希少疾患の治療薬開発に対する政府および経済的優遇措置
      • 希少医薬品の独占性の有無
    • 抑制要因
      • 希少医薬品に関連する高コスト
    • 機会
      • 研究開発の取り組みと新製品の開発の増加
      • 新興国における希少医薬品開発に対する規制上のインセンティブ
    • 課題
      • 希少医薬品に関連する副作用
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 希少医薬品市場:疾患タイプ別

  • 胃腸
  • 血液学
  • 感染症
  • 神経内科
  • 腫瘍学

第7章 希少医薬品市場:製品タイプ別

  • 生物学的
  • 非生物学的

第8章 希少医薬品市場:流通チャネル別

  • 病院薬局
  • 小売薬局
  • 専門薬局

第9章 南北アメリカの希少医薬品市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の希少医薬品市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの希少医薬品市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ORPHAN DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ORPHAN DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ORPHAN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)
  • FIGURE 5. ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2022 VS 2030 (%)
  • FIGURE 6. ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 7. ORPHAN DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. ORPHAN DRUGS MARKET DYNAMICS
  • FIGURE 9. ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ORPHAN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ORPHAN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. ORPHAN DRUGS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. ORPHAN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ORPHAN DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. ORPHAN DRUGS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ORPHAN DRUGS MARKET SIZE, BY NON-BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ORPHAN DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 146. ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 147. ORPHAN DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-036C5CF3B4BA

The Global Orphan Drugs Market is forecasted to grow significantly, with a projected USD 191.86 billion in 2023 at a CAGR of 13.32% and expected to reach a staggering USD 462.45 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Orphan Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Orphan Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Type, market is studied across Gastrointestinal, Hematology, Infectious Diseases, Neurology, Oncology, and Pulmonary. The Gastrointestinal is projected to witness significant market share during forecast period.

Based on Product Type, market is studied across Biologic and Non-Biologic. The Biologic is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Orphan Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Orphan Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Orphan Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Orphan Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Orphan Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Orphan Drugs Market?

6. What is the market share of the leading vendors in the Global Orphan Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Orphan Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Orphan Drugs Market, by Disease Type, 2022 vs 2030
  • 4.3. Orphan Drugs Market, by Product Type, 2022 vs 2030
  • 4.4. Orphan Drugs Market, by Distribution Channel, 2022 vs 2030
  • 4.5. Orphan Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in prevalence of rare diseases and increasing healthcare expenditure
      • 5.1.1.2. Favorable government and economic incentives for the development of drugs for rare diseases
      • 5.1.1.3. Availability of exclusivity for orphan drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with orphan drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D initiatives and development of novel products
      • 5.1.3.2. Regulatory incentives for the development of orphan drugs in emerging countries
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with orphan drugs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Orphan Drugs Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Gastrointestinal
  • 6.3. Hematology
  • 6.4. Infectious Diseases
  • 6.5. Neurology
  • 6.6. Oncology
  • 6.7. Pulmonary

7. Orphan Drugs Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biologic
  • 7.3. Non-Biologic

8. Orphan Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Retail Pharmacies
  • 8.4. Specialty Pharmacies

9. Americas Orphan Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Orphan Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Orphan Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing